KR20160079121A - 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 - Google Patents

류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 Download PDF

Info

Publication number
KR20160079121A
KR20160079121A KR1020167016059A KR20167016059A KR20160079121A KR 20160079121 A KR20160079121 A KR 20160079121A KR 1020167016059 A KR1020167016059 A KR 1020167016059A KR 20167016059 A KR20167016059 A KR 20167016059A KR 20160079121 A KR20160079121 A KR 20160079121A
Authority
KR
South Korea
Prior art keywords
weeks
subject
treatment
score
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167016059A
Other languages
English (en)
Korean (ko)
Inventor
시아오홍 후앙
마흐티네 자쏭
바네싸 마크
알렌 라딘
충펭 팬
휴버트 반 훅스트라텐
스테파노 피오레
자넷 반 아델스버그
마크 제노비스
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Priority to KR1020227013977A priority Critical patent/KR20220056254A/ko
Publication of KR20160079121A publication Critical patent/KR20160079121A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167016059A 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 Ceased KR20160079121A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227013977A KR20220056254A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US61/907,796 2013-11-22
US201462008787P 2014-06-06 2014-06-06
US62/008,787 2014-06-06
EP14306366.7 2014-09-05
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013977A Division KR20220056254A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Publications (1)

Publication Number Publication Date
KR20160079121A true KR20160079121A (ko) 2016-07-05

Family

ID=51518724

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237036134A Ceased KR20230155586A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
KR1020227013977A Ceased KR20220056254A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
KR1020167016059A Ceased KR20160079121A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020237036134A Ceased KR20230155586A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
KR1020227013977A Ceased KR20220056254A (ko) 2013-11-22 2014-11-21 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Country Status (11)

Country Link
US (1) US20160280782A1 (OSRAM)
EP (2) EP3770173A1 (OSRAM)
JP (3) JP6657089B2 (OSRAM)
KR (3) KR20230155586A (OSRAM)
CN (2) CN106413748A (OSRAM)
AU (3) AU2014352801B2 (OSRAM)
CA (1) CA2930615C (OSRAM)
MX (2) MX377190B (OSRAM)
PL (1) PL3071230T3 (OSRAM)
SG (1) SG10201804000TA (OSRAM)
WO (1) WO2015077582A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
WO2015077582A1 (en) * 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
KR20180073680A (ko) 2015-11-03 2018-07-02 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법
SG11201807614SA (en) * 2016-03-07 2018-10-30 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
US12295912B2 (en) 2017-12-07 2025-05-13 Zacros Corporation Port-equipped bag and cap-equipped bag
JP7504871B2 (ja) * 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
AU2020216978B2 (en) * 2019-01-31 2025-09-25 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
MA55760A (fr) * 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
BR112021024445A2 (pt) * 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
ES2799439T3 (es) * 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
WO2015077582A1 (en) * 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대

Also Published As

Publication number Publication date
AU2024204881A1 (en) 2024-08-15
CA2930615A1 (en) 2015-05-28
CN106413748A (zh) 2017-02-15
EP3770173A1 (en) 2021-01-27
CN120514847A (zh) 2025-08-22
SG10201804000TA (en) 2018-07-30
JP2022033891A (ja) 2022-03-02
KR20220056254A (ko) 2022-05-04
AU2020223706A1 (en) 2020-09-10
JP6657089B2 (ja) 2020-03-04
MX2020011993A (es) 2021-01-29
US20160280782A1 (en) 2016-09-29
MX2016006595A (es) 2016-09-06
EP3071230A1 (en) 2016-09-28
KR20230155586A (ko) 2023-11-10
AU2020223706B2 (en) 2024-04-18
MX377190B (es) 2025-03-07
CA2930615C (en) 2023-04-04
AU2014352801B2 (en) 2020-05-28
EP3071230B1 (en) 2020-04-08
JP2016539125A (ja) 2016-12-15
WO2015077582A1 (en) 2015-05-28
AU2014352801A1 (en) 2016-06-23
PL3071230T3 (pl) 2020-09-21
JP2024026223A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
AU2020223706B2 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP6336171B2 (ja) 関節リウマチを治療するための組成物およびこれを用いる方法
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
HK40044249A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
IL265949A (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1195495A (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1195495B (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191120

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211124

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210716

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200130

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191120

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211227

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211124

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210716

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210517

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200130

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191120

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220426